Table 1 Patient characteristics . Group... | American Society of Hematology

Table 1

Patient characteristics

	Group 1: AL without MM I, n = 75	Group 2: AL plus MM I, n = 10	Group 3: MGUS, n = 127*	Group 4: MM I, n = 19
Median age, y (range)	62 (39-81)	52 (45-70)	59 (30-84)	65 (41-77)
Sex, no. male/female	44/31	2/8	58/69	10/9
Light chain, no. kappa/lambda	18/57	3/7	80/46	8/11
Intact immunoglobulin, no. yes/no	34/41	7/3	122/5	19/0
Median plasma cell content, % (range)	10 (2-26)	17 (5-42)	9 (1-28)	28 (3-50)
Median LC urine, mg/d (range)†	99 (< 5-850)	1368 (< 5-2457)	< 5 (< 5-871)	37 (< 5-1960)
No. patients with MM stage I as defined by the value of serum M protein	0	0	0	11

	Group 1: AL without MM I, n = 75	Group 2: AL plus MM I, n = 10	Group 3: MGUS, n = 127*	Group 4: MM I, n = 19
Median age, y (range)	62 (39-81)	52 (45-70)	59 (30-84)	65 (41-77)
Sex, no. male/female	44/31	2/8	58/69	10/9
Light chain, no. kappa/lambda	18/57	3/7	80/46	8/11
Intact immunoglobulin, no. yes/no	34/41	7/3	122/5	19/0
Median plasma cell content, % (range)	10 (2-26)	17 (5-42)	9 (1-28)	28 (3-50)
Median LC urine, mg/d (range)†	99 (< 5-850)	1368 (< 5-2457)	< 5 (< 5-871)	37 (< 5-1960)
No. patients with MM stage I as defined by the value of serum M protein	0	0	0	11

Age and sex were statistically equally distributed between AL and MGUS, whereas lambda light chain restriction and intact immunoglobulin deficiency prevailed among patients with AL.

This group includes one patient with a gammopathy biclonal for kappa and lambda.

†

LC indicates light chain.

View Large

This Feature Is Available To Subscribers Only